Profile data is unavailable for this security.
About the company
OKYO Pharma Limited is a United Kingdom-based clinical stage biopharmaceutical company developing therapies for the treatment of dry eye disease (DED) and neuropathic corneal pain (NCP). The Company is focused on the discovery and development of novel molecules to treat inflammatory DED and ocular pain. Its research program is focused on a novel G Protein-Coupled Receptor (GPCR). The Company is developing OK-101, its lead preclinical product candidate, for the treatment of DED. OK-101 is focused on keratoconjunctivitis sicca, commonly referred to as DED, which is a multifactorial disease caused by an underlying inflammation resulting in the lack of lubrication and moisture in the surface of the eye. The Company also plans to evaluate its potential in benefiting patients with ocular neuropathic pain, uveitis and allergic conjunctivitis. It is also evaluating OK-201, a bovine adrenal medulla (BAM), lipidated-peptide preclinical analogue candidate that is in the developmental stage.
- Revenue in USD (TTM)0.00
- Net income in USD-8.53m
- Incorporated2018
- Employees7.00
- LocationOKYO Pharma LtdFloor 4, 14/15 Conduit StLONDON W1S 2XJUnited KingdomGBR
- Phone+44 207 495 2379
- Websitehttps://okyopharma.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inotiv Inc | 552.74m | -71.29m | 48.57m | 1.96k | -- | 0.2338 | -- | 0.0879 | -2.77 | -2.77 | 21.44 | 8.00 | 0.6565 | 7.18 | 7.91 | 282,733.50 | -8.58 | -23.84 | -13.63 | -29.26 | 28.76 | 29.31 | -13.07 | -33.24 | 0.2744 | -0.1734 | 0.6476 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Nanopharmaceutics Inc | 1.01m | -549.47k | 48.66m | 50.00 | -- | -- | -- | 48.20 | -0.0034 | -0.0034 | 0.0062 | -0.0508 | -- | -- | -- | 20,191.00 | -- | -- | -- | -- | 60.28 | -- | -110.51 | -- | 0.0417 | -433.32 | -- | -- | 0.3272 | -- | -39.70 | -- | -- | -- |
| Moolec Science SA | 2.65m | -52.66m | 50.09m | 45.00 | -- | 4.94 | -- | 18.94 | -1.44 | -1.44 | 0.0766 | 0.2367 | -- | -- | -- | 58,780.00 | -- | -- | -- | -- | 2.92 | -- | -1,990.79 | -- | 0.2243 | -0.1889 | 0.2372 | -- | -- | -- | -1,044.02 | -- | -- | -- |
| Lexaria Bioscience Corp | 404.72k | -5.44m | 50.13m | 5.00 | -- | 7.39 | -- | 123.85 | -0.6851 | -0.6851 | 0.0493 | 0.5264 | 0.0722 | -- | 1.64 | 80,944.00 | -97.62 | -95.67 | -94.18 | -96.58 | 95.66 | 76.98 | -1,351.64 | -1,612.76 | -- | -175.33 | 0.00 | -- | -11.43 | -12.19 | 8.31 | -- | -- | -- |
| OKYO Pharma Ltd | 0.00 | -8.53m | 50.37m | 7.00 | -- | -- | -- | -- | -11.01 | -11.01 | 0.00 | -0.0181 | 0.00 | -- | -- | 0.00 | -232.28 | -- | -393.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -55.13 | -- | -- | -- |
| Modular Medical Inc | 0.00 | -16.76m | 50.51m | 37.00 | -- | 9.03 | -- | -- | -0.9653 | -0.9653 | 0.00 | 0.1805 | 0.00 | -- | -- | 0.00 | -224.40 | -168.16 | -262.22 | -209.51 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 25.51 | -- | 154.53 | -- |
| Kezar Life Sciences Inc | 7.00m | -101.87m | 50.52m | 58.00 | -- | 0.2693 | -- | 7.22 | -1.40 | -1.40 | 0.0965 | 2.58 | 0.0269 | -- | -- | 120,689.70 | -39.12 | -32.54 | -41.41 | -34.09 | -- | -- | -1,455.29 | -4,308.11 | -- | -- | 0.051 | -- | -- | -- | -49.28 | -- | 10.08 | -- |
| Ocean Biomedical Holdings Inc | 0.00 | -45.58m | 50.93m | 9.00 | -- | -- | -- | -- | -1.40 | -1.40 | 0.00 | -0.0642 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -612.50 | -- | -- | -- |
| CASI Pharmaceuticals Inc | 28.94m | -30.48m | 51.78m | 176.00 | -- | 3.35 | -- | 1.79 | -2.28 | -2.28 | 2.16 | 1.15 | 0.3954 | 1.00 | 3.41 | 164,437.50 | -40.88 | -34.75 | -59.15 | -46.91 | 58.36 | 55.98 | -103.40 | -153.72 | 3.25 | -76.70 | 0.5458 | -- | -21.41 | -- | 34.27 | -- | 14.65 | -- |
| Carmell Corp | 0.00 | -18.29m | 51.80m | 9.00 | -- | -- | -- | -- | -1.58 | -1.49 | 0.00 | -0.0719 | 0.00 | -- | -- | 0.00 | -428.46 | -- | -- | -- | 58.60 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -75.70 | -- | -- | -- |
| Bright Green Corp | 0.00 | -11.46m | 52.24m | 5.00 | -- | 4.70 | -- | -- | -0.0631 | -0.0631 | 0.00 | 0.0584 | 0.00 | -- | -- | 0.00 | -56.05 | -- | -84.87 | -- | -- | -- | -- | -- | -- | -18,125.84 | 0.0289 | -- | -- | -- | 52.54 | -- | -- | -- |
| IN8BIO, Inc. | 0.00 | -31.04m | 52.51m | 31.00 | -- | 2.94 | -- | -- | -0.9154 | -0.9154 | 0.00 | 0.4049 | 0.00 | -- | -- | 0.00 | -123.61 | -74.18 | -145.63 | -84.42 | -- | -- | -- | -- | -- | -- | 0.0556 | -- | -- | -- | -5.21 | -- | -4.54 | -- |
| Equillium Inc | 37.89m | -12.13m | 52.88m | 44.00 | -- | 2.51 | -- | 1.40 | -0.3476 | -0.3476 | 1.08 | 0.5983 | 0.6568 | -- | 8.95 | 861,227.30 | -21.02 | -46.81 | -39.66 | -57.36 | -- | -- | -32.01 | -328.35 | -- | -- | 0.00 | -- | 128.97 | -- | 78.64 | -- | 7.48 | -- |
| DURECT Corp | 8.32m | -23.28m | 53.08m | 48.00 | -- | 6.39 | -- | 6.38 | -0.8653 | -0.8653 | 0.2976 | 0.2674 | 0.176 | 0.7021 | 6.87 | 143,465.50 | -49.23 | -37.34 | -167.81 | -53.44 | 80.56 | 91.83 | -279.77 | -139.11 | 0.9575 | -47.70 | 0.6377 | -- | -55.67 | -10.96 | 21.82 | -- | -10.98 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -9.35m | 53.16m | 2.00 | -- | 10.66 | -- | -- | -0.3633 | -0.3633 | 0.00 | 0.1922 | 0.00 | -- | -- | 0.00 | -91.51 | -- | -104.28 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -71.89 | -- | -- | -- |
| Rockwell Medical Inc | 86.62m | -8.42m | 53.20m | 237.00 | -- | 2.51 | -- | 0.6142 | -0.3584 | -0.3584 | 3.33 | 0.6984 | 1.90 | 13.28 | 10.12 | 365,485.20 | -18.47 | -46.29 | -27.53 | -65.38 | 10.59 | 4.66 | -9.72 | -36.51 | 1.38 | -3.54 | 0.331 | -- | 14.84 | 5.69 | 54.82 | -- | 76.21 | -- |
Data as of May 31 2024. Currency figures normalised to OKYO Pharma Ltd's reporting currency: US Dollar USD
2.75%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Barclays Bank Plc (Private Banking)as of 31 Mar 2024 | 855.89k | 2.58% |
| G1 Execution Services LLCas of 31 Mar 2024 | 20.31k | 0.06% |
| Cerity Partners LLCas of 31 Mar 2024 | 13.31k | 0.04% |
| Geode Capital Management LLCas of 31 Mar 2024 | 12.09k | 0.04% |
| HSBC Bank Plc (Broker)as of 31 Mar 2024 | 11.93k | 0.04% |
| Continuum Advisory LLCas of 31 Mar 2024 | 50.00 | 0.00% |
| Morgan Stanley & Co. LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
